|
|
|
Volumn 13, Issue 1, 1999, Pages 82-
|
|
NCI to sponsor phase III trials of liquid shark cartilage angiogenesis inhibitor
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AE 941;
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
UNCLASSIFIED DRUG;
ARTICLE;
CANCER THERAPY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE CALCULATION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG SCREENING;
DRUG TOLERABILITY;
HEALTH SERVICE;
HUMAN;
MULTICENTER STUDY;
ORAL DRUG ADMINISTRATION;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
SHARK;
ADMINISTRATION, ORAL;
ANTI-INFLAMMATORY AGENTS;
CARTILAGE;
CLINICAL TRIALS, PHASE III;
HUMANS;
MULTICENTER STUDIES;
NATIONAL INSTITUTES OF HEALTH (U.S.);
NEOPLASMS;
NEOVASCULARIZATION, PATHOLOGIC;
TISSUE EXTRACTS;
UNITED STATES;
|
|
EID: 0032909363
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|